• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by LifeMD Inc.

    11/12/25 5:16:12 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care
    Get the next $LFMD alert in real time by email
    NT 10-Q 1 formnt10-q.htm NT 10-Q

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ⌧ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

    For Period Ended: September 30, 2025

     

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

    PART I-REGISTRANT INFORMATION

     

    LifeMD Inc.  
    Full name of Registrant  
       
    Conversion Labs, Inc.  
    Former name if Applicable  
       
    236 Fifth Avenue, Suite 400  
    Address of Principal Executive Office (Street and number)  
       
    New York, NY 10001  
    City, State and Zip Code  

     

     

     

     
     

     

    PART II-RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

      (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
         
    ⌧ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, FORM N-CEN or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
         
      (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    LifeMD, Inc. (the “Company”) has determined that it was unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the “Form 10-Q”) by November 10, 2025, the original due date for such filing, without unreasonable effort or expense because it requires additional time to complete its financial statements. The Company requires additional time to finalize adjustments necessary to correct errors related to the over-recognition of revenue. The Company has identified approximately $4.6 million in cumulative over recognition of revenue, with offsetting amounts in the related balance sheet accounts, in its filings for quarterly and annual periods between 2022 and June 30, 2025. The required adjustments to correct the errors will not impact the Company’s cash flow or cash position. The Company is also evaluating the potential impact of these matters on internal control over financial reporting.

     

    Cautionary Note Regarding Forward Looking Statements

     

    This filing includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements regarding the impact of recently discovered errors that originated in prior periods and were identified by the Company in the preparation of its third quarter 2025 financial statements that the Company is evaluating, including the potential impact of these matters on internal control over financial reporting. Forward-looking statements contained in this filing may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. The preliminary determinations above are subject to adjustment as the Company prepares its financial statements and disclosures for the three and nine months ended September 30, 2025, and such adjustments may be significant. The Company’s current and former independent registered public accounting firms have not audited, reviewed, compiled, or applied agreed-upon procedures with respect to the preliminary estimates set forth above. Factors that could materially affect these forward looking statements include, but are not limited to: the completion of the review of the accounting matters identified, including the potential impact on internal control over financial reporting, as well as those factors set forth in our Form 10-K (and other forms) filed with the Securities and Exchange Commission.

     

     
     

     

    Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

     

    Any forward-looking statement made in this filing is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification.

     

     

    Marc Benathen

      (917)   902-3689
     

    (Name)

      (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ⌧ Yes ☐ No

     

    (3)

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes ⌧ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

     
     

     

      LifeMD, Inc.  
      (Name of Registrant as Specified in Charter)  

     

    has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

     

    Date: November 12, 2025 By: /s/ Marc Benathen
        Marc Benathen
        Chief Financial Officer

     

     

    Get the next $LFMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFMD

    DatePrice TargetRatingAnalyst
    6/18/2025$15.00 → $18.00Buy
    BTIG Research
    12/10/2024$12.00Buy
    Lake Street
    12/4/2024$7.00Neutral
    Mizuho
    8/23/2024$11.00Buy
    B. Riley Securities
    6/5/2024$12.00Overweight
    KeyBanc Capital Markets
    11/30/2023$10.00Buy
    Craig Hallum
    7/21/2023$7.00Overweight
    Cantor Fitzgerald
    7/3/2023$9.00Buy
    H.C. Wainwright
    More analyst ratings

    $LFMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk

    NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced a new, lower cash-pay price for GLP-1 medications, Wegovy® and Ozempic®, made possible through its ongoing collaboration with Novo Nordisk. LifeMD will now offer the 0.25 mg and 0.5 mg doses at $199 per month—the lowest cash-pay pricing available nationwide—for two fills for new patients. The offering is designed to support patients who pay out of pocket. These medications are available through the LifeMD Weight Management Program, which provides comprehensive support including virtual consultations with LifeMD's dedicated clinical team,

    11/17/25 8:00:55 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Participate in the BTIG Digital Health Forum

    NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital Health Forum on November 24, 2025. Management will participate in a virtual panel discussion titled "Creating a Scalable Virtual Primary Care and Obesity Health Platform" at 4:00 p.m. Eastern time and will be available for one-on-one virtual meetings. Investors can register for the conference by contacting their BTIG representative. About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialize

    11/10/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD's third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 202

    11/5/25 5:15:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Strawn John R Jr was granted 22,365 shares, increasing direct ownership by 6% to 413,001 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:25:50 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Larovere Joan was granted 22,365 shares, increasing direct ownership by 26% to 107,050 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/8/25 6:03:32 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Director Ditrolio Joseph was granted 22,365 shares, increasing direct ownership by 9% to 273,413 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    10/6/25 6:53:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    BTIG Research reiterated coverage on LifeMD with a new price target

    BTIG Research reiterated coverage of LifeMD with a rating of Buy and set a new price target of $18.00 from $15.00 previously

    6/18/25 10:55:14 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Lake Street initiated coverage on LifeMD with a new price target

    Lake Street initiated coverage of LifeMD with a rating of Buy and set a new price target of $12.00

    12/10/24 8:29:49 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Mizuho initiated coverage on LifeMD with a new price target

    Mizuho initiated coverage of LifeMD with a rating of Neutral and set a new price target of $7.00

    12/4/24 7:42:36 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    SEC Filings

    View All

    $LFMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 10-Q filed by LifeMD Inc.

    10-Q - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:52:52 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - LifeMD, Inc. (0000948320) (Filer)

    11/17/25 4:10:58 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form NT 10-Q filed by LifeMD Inc.

    NT 10-Q - LifeMD, Inc. (0000948320) (Filer)

    11/12/25 5:16:12 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    Chief Innovation Officer Galluppi Stefan bought $14,790 worth of shares (3,000 units at $4.93), increasing direct ownership by 7% to 45,449 units (SEC Form 4)

    4 - LifeMD, Inc. (0000948320) (Issuer)

    9/12/24 2:10:03 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Leadership Updates

    Live Leadership Updates

    View All

    LifeMD Names COO and Promotes Two Executives

    NEW YORK, July 31, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services, today announced the appointment of Shayna Webb Dray as its Chief Operating Officer. Ms. Webb Dray, an accomplished operations and supply chain executive with over 15 years of experience, has been an integral part of LifeMD's growth, most recently serving as Senior Vice President of Operations. "Shayna's proven track record of building and managing an industry-leading operations team and infrastructure in a complex and rapidly growing environment makes her the ideal leader to step into the role of COO," said Justin Schreiber, Chairman and Chief Executive Officer of L

    7/31/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Set to Join the Russell 3000 Index

    NEW YORK, May 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, is set to join the broad-market Russell 3000® Index at the conclusion of the 2024 Russell U.S. Indexes annual reconstitution, effective at the open of U.S. equity markets on Monday, July 1st, according to a preliminary list of additions posted Friday, May 24th. The annual Russell U.S. Indexes reconstitution captures the 4,000 largest U.S. stocks as of Tuesday, April 30th, ranking them by total market capitalization. Membership in the U.S. all-cap Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Ind

    5/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Appoints Dr. Calum MacRae to its Board of Directors

    NEW YORK, April 29, 2024 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the appointment of Calum MacRae, M.D., Ph.D., a clinician, researcher and educator at Harvard Medical School, as an independent member of its Board of Directors. "We are delighted to welcome Dr. MacRae to the LifeMD Board of Directors. He brings deep experience in cardiology, internal medicine and clinical innovation, with a focus on disease management and the implementation of novel solutions to improve the delivery of virtual healthcare services," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "Aside from being a world-reno

    4/29/24 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by LifeMD Inc.

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    11/14/24 10:42:44 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G/A filed by LifeMD Inc. (Amendment)

    SC 13G/A - LifeMD, Inc. (0000948320) (Subject)

    2/14/24 3:33:22 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by LifeMD Inc.

    SC 13G - LifeMD, Inc. (0000948320) (Subject)

    10/6/23 5:26:16 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    $LFMD
    Financials

    Live finance-specific insights

    View All

    LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17

    NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quarter 2025 earnings release and conference call to Monday, November 17, 2025. The Company expects to file a Form 12b-25, as needed, notifying the U.S. Securities and Exchange Commission of a late filing of its Form 10-Q for the period ended September 30, 2025. The change to LifeMD's third quarter 2025 earnings release date relates to corrections the Company identified related to the recognition of revenue with offsetting related balance sheet accounts for the twelve months ended December 31, 202

    11/5/25 5:15:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD to Report Third Quarter 2025 Financial Results on November 6

    NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on November 6, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-245-3047International Dial-In:203-518-9765Conference ID:LIFEMDLive & Archived Webcast:Link   About LifeMD, Inc. LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and ph

    10/23/25 8:00:00 AM ET
    $LFMD
    Medical/Nursing Services
    Health Care

    LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

    NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividend to holders of the Company's 8.875% Series A Cumulative Perpetual Preferred Stock (NASDAQ:LFMDP) equal to $0.5546875 per share. The preferred dividend will be paid on October 15, 2025, to holders of record at the close of business on October 3, 2025. About LifeMD, Inc.LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's

    9/23/25 4:05:00 PM ET
    $LFMD
    Medical/Nursing Services
    Health Care